CTRI/2024/02/062212进行中（未招募）Unknown
A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, bioequivalence study with clinical endpoint comparing generic bimatoprost ophthalmic solution 0.01% and LUMIGAN® (bimatoprost ophthalmic solution) 0.01% in the treatment of subjects with chronic open-angle glaucoma or ocular hypertension in both eyes. - NI
Dr. Ilesh Changela0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Subjects willing and able to provide voluntary informed consent and to follow protocol requirements.
- •2. Male or females aged greater than or equal to18 years.
- •3. Subjects with chronic open-angle glaucoma or ocular hypertension in both eyes
- •4. Subjects requiring treatment of both eyes and able to discontinue the use of all ocular hypotensive medications or switch ocular hypotensive medications and undergo appropriate washout period.
- •5. Adequate washout period prior to baseline of any ocular hypotensive medications as per the table below (to minimize potential risk to subjects due to intraocular pressure elevations during the washout period, the Investigator may choose to substitute a parasympathomimetic or carbonic anhydrase inhibitor in place of a sympathomimetic, alpha agonist, beta-adrenergic blocking agent, or prostaglandin, however, all the subjects must have discontinued their ocular hypotensive medications for the minimum washout period provided in the table below).
- •Parasympathomimetics (eg. pilocarpine, carbachol)4 days
- •Carbonic anhydrase inhibitors (systemic or topical) (eg. acetazolamide, dorzolamide hydrochloride, brinzolamide)4 days
- •Sympathomimetics (eg. dipivefrin, epinephrine)2 weeks
- •Alpha-agonists (eg. apraclonidine, brimonidine tartrate, brimonidine tartrate and brinzolamide combination)2 weeks
- •Beta-adrenergic blocking agents (eg. timolol, timolol maleate and dorzolamide hydrochloride combination, timolol maleate and brimonidine tartrate combination, levobunolol, betaxolol, metipranolol, carteolol)4 weeks
- •Prostaglandin analogs (eg. latanoprost, travoprost, bimatoprost, tafluprost)4 weeks
- •Osmotic agents
- •(eg. Mannitol, Isosorbide, Glycerin)4 days
- •Rho kinase inhibitors (eg. Ripasudil, Netarsudil)4 weeks
- •7. Subjects IOP is likely to be controlled with monotherapy as per the Investigators discretion.
- •8. Baseline best corrected visual acuity equivalent to Snellen acuity of 20 by 100 or better in each eye, using a logarithmic visual acuity chart for testing at 10 feet (3 meters).
- •9. Women of childbearing potential (defined as women physiologically capable of becoming pregnant unless they are using an effective method of contraception during the dosing of the study drug) practicing any of the following acceptable methods of contraception:
- •a. Oral or parenteral (injection, patch, or implant) hormonal contraception which has been continuously used for at least 1 month prior to first dose of study medication.
- •b. Intrauterine device or intrauterine system
- •c. Double barrier method of contraception (condom and occlusive cap or condom and spermicidal agent)
- •d. Male sterilization (at least 6 months prior to screening, should be the sole male partner for that subject)
- •e. Female sterilization (surgical bilateral oophorectomy) or tubal ligation at least 6 weeks prior to study participation
- •f. Total abstinence, partial abstinence is not acceptable
- •10. No history of addiction to any recreational drug or drug dependence or alcohol addiction
排除标准
- •1. Female who are pregnant, lactating or planning a pregnancy.
- •2. Subjects recently diagnosed with open-angle glaucoma or ocular hypertension and who are treatment naive.
- •3. Contraindication or known hypersensitivity to Bimatoprost, related class of drugs, or any of the excipients of formulation.
- •4. Current or history of severe hepatic or renal impairment.
- •5. Current or history within 2 months prior to baseline of any other significant ocular disease, eg. corneal edema, uveitis, ocular infection, or ocular trauma in either eye (Note: stable myopia, strabismus, and cataracts as per the Investigator’s discretion will be allowed provided that the other inclusion or exclusion criteria are met).
- •6. Current corneal abnormalities that would prevent accurate IOP readings with Goldmann applanation tonometer.
- •7. Functionally significant visual field loss in the Investigators’ opinion.
- •8. Subject with corneal grafts.
- •9. Subject has contraindication to pupil dilation.
- •10. Use at any time prior to baseline of an intraocular corticosteroid implant.
- •11. Use of contact lens within 1 week prior to baseline.
- •12. Use within 2 weeks prior to baseline of 1) a topical ophthalmic corticosteroid or 2) a topical corticosteroid.
- •13. Use within 1 month prior to baseline of 1) a systemic corticosteroid or 2) high dose salicylate therapy defined as 325 mg per day and taken on 3 consecutive days.
- •14. Use within 6 months prior to baseline of intravitreal or subtenon injection of ophthalmic corticosteroid.
- •15. Underwent within 6 months prior to baseline any other intraocular surgery (eg. cataract surgery).
- •16. Underwent within 12 months prior to baseline any refractive surgery, filtering surgery, or laser surgery for IOP reduction (eg. laser trabeculoplasty).
- •17. Amblyopia only one sighted eye.
- •18. Subjects with a history of IOP previously uncontrolled on bimatoprost monotherapy.
- •19. Significant ocular surface findings (eg. hyperemia or irritation, mild or greater) in either eye found on gross macroscopic or slit lamp examination.
- •20. Severe retinal disease or other severe ocular pathology, such as glaucomatous damage with a cup or disk ratio greater than 0.8 (not including physiological cupping in the Investigators opinion) or split fixation.
- •21. Chronic use of any systemic medication that may affect IOP with less than 3 months stable dosing regimen (ie. sympathomimetic agents, beta-adrenergic blocking agents, alpha-agonists, alpha-adrenergic blocking agents, calcium channel blockers, angiotensin-converting enzyme inhibitors, etc.)
- •23. Known history or presence of any uncontrolled systemic disease (eg. cardiovascular disease, hypertension, diabetes mellitus, hepatic impairment, etc.)
- •24. History of recurrent ocular seasonal allergies within the past 2 years.
- •25. Any other medical condition or serious intercurrent illness that, in the Investigators opinion, may make it undesirable for the subject to participate in the study and would limit adherence to the study requirements.
- •26. Participation in any clinical study within 30 days before the first dose of study drug.
- •27. Subjects with known history of positive serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV).
- •28. Subjects with positive urine pregnancy test.
研究者
相似试验
进行中（未招募）
1 期
Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients with Mild to Moderate HypertensioMedDRA version: 20.0Level: PTClassification code 10012601Term: Diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersDiabetes mellitusEUCTR2017-002309-36-DESANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT40
进行中（未招募）
1 期
Assess Safety and Efficacy of Vilaprisan in Subjects with Uterine FibroidseiomyomaMedDRA version: 20.0Level: LLTClassification code 10046784Term: Uterine fibroidsSystem Organ Class: 100000021126MedDRA version: 20.0Level: LLTClassification code 10016628Term: FibroidsSystem Organ Class: 100000021126MedDRA version: 20.0Level: LLTClassification code 10022794Term: Intramural leiomyoma of uterusSystem Organ Class: 100000021126EUCTR2016-002855-48-BEBayer AG996
进行中（未招募）
1 期
Assess Safety and Efficacy of Vilaprisan in Subjects with Uterine FibroidseiomyomaMedDRA version: 19.1 Level: LLT Classification code 10046784 Term: Uterine fibroids System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10016628 Term: Fibroids System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10022794 Term: Intramural leiomyoma of uterus System Organ Class: 100000004864EUCTR2016-002855-48-ESBayer AG996
进行中（未招募）
1 期
Assess Safety and Efficacy of Vilaprisan in Subjects with Uterine FibroidseiomyomaMedDRA version: 19.1Level: LLTClassification code 10046784Term: Uterine fibroidsSystem Organ Class: 100000004864MedDRA version: 19.1Level: LLTClassification code 10016628Term: FibroidsSystem Organ Class: 100000004864MedDRA version: 19.1Level: LLTClassification code 10022794Term: Intramural leiomyoma of uterusSystem Organ Class: 100000004864EUCTR2016-002855-48-HUBayer AG996
进行中（未招募）
1 期
Assess Safety and Efficacy of Vilaprisan in Subjects with Uterine FibroidsleiomyomaEUCTR2016-002855-48-ITBAYER HEALTHCARE AG996